Companies › Institut de Recherches Internationales Servier (I.R.I.S.)
2 active drug programs in 10 registered trials: 5 Phase 1, 3 Phase 3, 2 Phase 2; Oncology, Gastroenterology; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Vorasidenib IDH1/IDH2 inhibitor; Isocitrate dehydrogenase [NADP], mitochondrial inhibitor; Isocitrate dehydrogenase [NADP] cytoplasmic inhibitor | IDH1, IDH2 | Phase 2 | Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation; Severe Hepatic Impairment; Grade 2 Glioma; Astrocytoma, IDH-Mutant, Grade 3 … | Nov 2026 |
| BN104 unclear - specific molecular target not stated | – | Phase 1 | ALL, Adult; Menin Inhibitors | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07250633 | Vorasidenib | Phase 1 | Severe Hepatic Impairment | Gastroenterology | Nov 2026 |
| NCT06052813 | BN104 | Phase 1 | ALL, Adult | Oncology | Dec 2026 |
| NCT05609994 | Vorasidenib | Phase 1 | Low Grade Glioma of Brain | Oncology | Aug 2027 |
| NCT05484622 | Vorasidenib | Phase 1 | Astrocytoma | Oncology | Aug 2027 |
| NCT06478212 | Vorasidenib | Phase 1 | IDH1-mutant Glioma | Oncology | Nov 2027 |
| NCT07101497 | BN104 | Phase 2 | Menin Inhibitors | Oncology | Dec 2027 |
| NCT04164901 | Vorasidenib | Phase 3 | Grade 2 Glioma | Oncology | May 2028 |
| NCT07286292 | Vorasidenib | Phase 2 | Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation | Oncology | May 2033 |
| NCT07215910 | Vorasidenib | Phase 3 | Astrocytoma, IDH-Mutant, Grade 3 | Oncology | May 2033 |
| NCT06809322 | Vorasidenib | Phase 3 | IDH-mutant Grade 2 or 3 Astrocytoma | Oncology | Apr 2035 |
Servier Servier Affaires Médicales Zhejiang Doer Biologics Tianjin ConjuStar Biologics Zhejiang Hisun Pharmaceutical
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.